<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20110420006239N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-06-07</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>Evaluating the Effectiveness of Red and Infrared Low Level laser Therapy on Pain Control after Removal of Impacted Wisdom Teeth</public_title>
      <acronym>LLLT</acronym>
      <scientific_title>Comparison of the Effectiveness of Red and Infrared Low level Laser Therapy  for Post Operative Pain Control,Swelling and Trismus in Patients with Impacted Mandibular Third Molar</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-04-09</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/38352</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization is achieved through www.randomization.org website in 3 groups of 10 from number 1 to 30, Blinding description: Switching on /off of the laser therapy device is controlled by the responsible nurse and the patient and the researcher are blind.</study_design>
      <phase>3</phase>
      <hc_freetext>Condition 1: Trismus. Condition 2: Pain. Condition 3: Swelling. Condition 4: Total analgesic drug consumption.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:In first group red laser(with the wavelength of 660 nm and  the power of 6 joules per square centimeter)is applied extraorally on 2 occasions, once 30 minutes before the impacted lower 3rd molar surgery and the other one is performed on the second day after operation. Irradiation will be performed by positioning the laser probe in contact with the skin on four points of the masseter muscle: 1 –, lower region (near the mandibular insertion); 2 –, lower middle region; 3 –, upper middle region; and 4 –, upper region (near the insertion of the zygomatic arch). The laser will be applied for 7 minutes at each point. Intervention 2: Intervention group: In the second group infra red laser(with the wavelength of 890 nm and  the power of 6 joules per square centimeter) is applied extraorally on 2 occasions, once 30 minutes before the impacted lower 3rd molar surgery and the other one is performed on the second day after operation. Irradiation will be performed by positioning the laser probe in contact with the skin on four points of the masseter muscle: 1 –, lower region (near the mandibular insertion); 2 –, lower middle region; 3 –, upper middle region; and 4 –, upper region (near the insertion of the zygomatic arch).The laser will be applied for 5 minutes at each point. Intervention 3: Control group: Placebo laser(off laser) is applied extraorally on 2 occasions, once 30 minutes before the impacted lower 3rd molar surgery and the other one is performed on the second day after operation. Placebo laser therapy will be performed by positioning the laser probe in contact with the skin on four points of the masseter muscle: 1 –, lower region (near the mandibular insertion); 2 –, lower middle region; 3 –, upper middle region; and 4 –, upper region (near the insertion of the zygomatic arch).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is No more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Javad Yazdani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Dentistry, Tabriz University of Medical Sciences, Golgasht Ave.</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166614766</zip>
        <telephone>+98 41 3336 6965</telephone>
        <email>Yazdanij@tbzmed.ac.ir</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Javad Yazdani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Dentistry faculty of Tabriz, Golgasht Ave.</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166614766</zip>
        <telephone>+98 41 3335 5965</telephone>
        <email>Yazdanij@tbzmed.ac.ir</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients admitted to the dental clinic who require the removal of impacted lower 3rd molar
Patients who have impacted lower 3rd molar with grade lllB or IIIC surgical difficulty according to Pell-Gregory classification
Patients who have mesioangular impacted lower 3rd molar
Patients without any systemic disease</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>35 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients with distoangular or vertical impacted lower 3rd molar
Soft tissue impaction of the lower 3rd molar
Hypersensitivity to local anesthetics
Patients with systemic disease
Local infection
Blood dyscrasias
Patients with a history of gastric ulcer or patients who are currently suffering from a gastric ulcer
Cardiovascular condition
Pregnancy
Lactation
Patients who have used analgesic or anti inflammatory drugs 24 hours prior surgery
Surgical procedures taking longer than 20 minutes</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>R25.2</hc_code>
      <hc_code>R52</hc_code>
      <hc_code>R60</hc_code>
      <hc_code>Y45.3</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Cramp and spasm</hc_keyword>
      <hc_keyword>Pain, unspecified</hc_keyword>
      <hc_keyword>Edema, not elsewhere classified</hc_keyword>
      <hc_keyword>Other nonsteroidal anti-inflammatory drugs [NSAID]</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:In first group red laser(with the wavelength of 660 nm and  the power of 6 joules per square centimeter)is applied extraorally on 2 occasions, once 30 minutes before the impacted lower 3rd molar surgery and the other one is performed on the second day after operation. Irradiation will be performed by positioning the laser probe in contact with the skin on four points of the masseter muscle: 1 –, lower region (near the mandibular insertion); 2 –, lower middle region; 3 –, upper middle region; and 4 –, upper region (near the insertion of the zygomatic arch). The laser will be applied for 7 minutes at each point.</i_keyword>
      <i_keyword>Intervention group: In the second group infra red laser(with the wavelength of 890 nm and  the power of 6 joules per square centimeter) is applied extraorally on 2 occasions, once 30 minutes before the impacted lower 3rd molar surgery and the other one is performed on the second day after operation. Irradiation will be performed by positioning the laser probe in contact with the skin on four points of the masseter muscle: 1 –, lower region (near the mandibular insertion); 2 –, lower middle region; 3 –, upper middle region; and 4 –, upper region (near the insertion of the zygomatic arch).The laser will be applied for 5 minutes at each point.</i_keyword>
      <i_keyword>Control group: Placebo laser(off laser) is applied extraorally on 2 occasions, once 30 minutes before the impacted lower 3rd molar surgery and the other one is performed on the second day after operation. Placebo laser therapy will be performed by positioning the laser probe in contact with the skin on four points of the masseter muscle: 1 –, lower region (near the mandibular insertion); 2 –, lower middle region; 3 –, upper middle region; and 4 –, upper region (near the insertion of the zygomatic arch).</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain. Timepoint: Day 2 post-operation,  day 7 post-operation. Method of measurement: Visual analog scale (asking from patient, scoring from 1 to 10).</prim_outcome>
      <prim_outcome>Swelling. Timepoint: Pre-operation, day 2 post-operation, day 7 post-operation. Method of measurement: Measuring 3 parameters: 1-tragus-labial commissure distance, 2-  Lateral canthus of eye-mandibular angle distance, 3-tragus–pogonion distance.</prim_outcome>
      <prim_outcome>Trismus. Timepoint: Pre-operation, day 2 post-operation, day 7 post-operation. Method of measurement: Measuring the maximum space between central incisors of maxilla and mandible( in millimeter).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Number of pain relief tablets taken. Timepoint: Day 2 post-operation, day 7 post-operation. Method of measurement: Asking the patient.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-03-11</approval_date>
        <contact_name>Ethics committee of Tabriz University of Medical Sciences</contact_name>
        <contact_address>Dentistry faculty of Tabriz, Golgasht Ave. Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
